Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) belong to the most common chronic inflammatory diseases (CIDs). While significant research efforts have led to improvements in treatment, ...

Patients with rheumatoid arthritis (RA) face heightened risks for COVID-19 infection, hospitalization, and mortality, according to results of a systematic review and meta-analysis published in BMC ...

Adalimumab trough levels of 4.0 mg/L or higher among patients with RA were linked to greater treatment response and achievement of remission.

In recent years treatment with powerful biologic and targeted synthetic therapies has changed the landscape for arthritis, but currently finding the right treatment for each person is a matter of ...

The study suggests that this gut bacterium may drive the immune response leading to RA in people who are genetically or ...

Discover how Native Americans face disproportionately high premature mortality from rheumatoid arthritis (RA), with rates far ...

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis.

MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Rheumatoid Arthritis.